Middle East

DCGI allows Bharat Biotech to conduct intranasal booster dose testing

New Delhi: In a major development on Friday, India’s Drug Controller General (DCGI) has allowed Hyderabad-based vaccine maker Bharat Biotech to conduct clinical trials of intranasal covid booster doses in India.

Clinical trials will be conducted at nine different sites, including AIIMS Delhi.

Vaccine makers have proposed additional immune doses for those who have already been vaccinated with the Covishield and Covaxin vaccines.

MS Education Academy

“Granting permission to conduct clinical trials using a vaccine conveys or implies that permission to sell this vaccine domestically is automatically granted based on the clinical trial data generated by the vaccine. It’s not a thing, “said the national drug regulator.

Bharat Biotech will conduct clinical trials in both Covishield and Covaxin vaccinated individuals. According to sources, the study will be conducted in half of the individuals who received Covishield and the other half who received Covacin.

A gap of approximately 6 months is expected between the second vaccination and the intranasal booster.

Intranasal vaccines reportedly have the potential to prevent the transmission of new Covid variants.

subscribe SiasatDaily-Google News

https://www.siasat.com/dcgi-permits-bharat-biotech-to-conduct-trials-for-intranasal-booster-dose-2266110/ DCGI allows Bharat Biotech to conduct intranasal booster dose testing

Back to top button